CytoSorbents Q2 2026 presentation omits financials; targets H2 2026 break-even

Cytosorbents Corp

2026-Q2 EPS reported -$0.15 vs consensus -$0.05 ▼ miss (-226.8%)

Targets operating cash-flow break-even in H2 2026 via strategic workforce and cost reduction plan.
Restructuring direct sales team and strategy in Germany; cites war in Iran as a risk factor.
Seeks FDA and Health Canada regulatory approval; must comply with existing debt covenants.
Q2 2026 earnings presentation dated Aug 6, 2026; no specific revenue or EPS figures in furnished exhibit.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.